Thymalfasin
Trials 53 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04963712 | Sep 2021 → Jul 2022 | HIV infectious disease | Shanghai Public Health Clinical Center | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06821100 | Dec 2024 → Dec 2026 expected | — | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT00001036 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02906163 | Oct 2016 → Dec 2019 | lung cancer | SciClone Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT02646189 | Aug 2011 → Aug 2013 | chronic hepatitis B virus infection | Replicor Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00580450 | Dec 2007 | hematopoietic and lymphoid cell neoplasm | University Of Perugia | Unknown | No outcome recorded |
| Phase 223 trials | ||||||
| Phase 2 | NCT07103395 | Jan 2026 → Dec 2029 expected | non-small cell lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07103408 | Oct 2025 → Sep 2029 expected | small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06829355 | Feb → Dec 2025 overdue | colorectal cancer | Beijing Friendship Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06573398 | Sep 2024 → Sep 2025 overdue | pancreatic ductal adenocarcinoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06584006 | Sep 2024 → Nov 2027 expected | hematopoietic and lymphoid cell neoplasm, lymphopenia | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06461910 | Jun 2024 → Jan 2026 overdue | gastric cancer, gastroesophageal junction adenocarcinoma | Zekuan Xu | Recruiting | No outcome recorded |
| Phase 2 | NCT06056804 | Jan → Dec 2024 overdue | — | Beijing Friendship Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06139419 | Jul 2023 → Aug 2026 overdue | non-small cell lung carcinoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07644897 | May 2023 → May 2027 expected | melanoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT05790447 | Apr 2023 → May 2025 | neoplasm | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT04428008 | Jan 2021 → Jan 2023 | COVID-19 | William B. Ershler, MD | Completed | No outcome recorded |
| Phase 2 | NCT04487444 | Sep 2020 → Feb 2023 | COVID-19 | Rhode Island Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT03659578 | Aug 2018 → Sep 2021 | non-small cell lung carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT02976740 | Nov 2016 → Jun 2019 | lung cancer | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
| Phase 2 | NCT02906150 | Sep 2016 → May 2019 | non-small cell lung carcinoma | SciClone Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT02787447 | May 2016 → Dec 2017 | lung adenocarcinoma | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| Phase 2 | NCT02542930 | Jan 2016 → Dec 2018 | non-small cell lung carcinoma | Zhejiang Provincial People's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT02545751 | Jan 2016 → Dec 2017 | esophageal cancer | Hangzhou Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02542137 | Sep 2015 → Dec 2018 | small cell lung carcinoma | Zhejiang Provincial People's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT02535988 | Sep 2015 → Jan 2017 | colorectal cancer | Zhejiang Provincial People's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT01031966 | Nov 2009 → May 2010 | end stage renal failure | sigma-tau i.f.r. S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00911443 | Jul 2002 → Sep 2007 | melanoma | sigma-tau i.f.r. S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00082082 | — | hepatocellular carcinoma | SciClone Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07675980 | Feb 2026 → Feb 2027 expected | infertility disorder | Fakih IVF Fertility Center | Recruiting | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT05086614 | Apr 2021 → Mar 2027 expected | colorectal carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT04320238 | Jan → May 2020 | COVID-19 | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 3 | NCT02867267 | Sep 2016 → Jan 2021 | infectious disease with sepsis | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT01178996 | Dec 2004 → May 2008 | chronic hepatitis C virus infection | sigma-tau i.f.r. S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00039962 | May 2002 → ? | chronic hepatitis C virus infection | SciClone Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00040027 | Apr 2002 → ? | chronic hepatitis C virus infection | SciClone Pharmaceuticals | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT06178146 | Sep 2023 → Nov 2024 | — | Jun Wang | Unknown | No outcome recorded |
| Phase 4 | NCT04524169 | Nov 2020 → Dec 2021 | osteoporosis | RenJi Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02473406 | Mar 2018 → Dec 2020 | acute necrotizing pancreatitis | Weiqin Li | Completed | No outcome recorded |
| Phase 4 | NCT03448744 | Oct 2017 → Dec 2018 | chronic hepatitis B virus infection | Wen-hong Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT02883595 | Mar → Sep 2016 | infectious disease with sepsis | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT02281266 | Jan 2015 → Jun 2018 | hepatocellular carcinoma | Jia Fan | Unknown | No outcome recorded |
| Phase 4 | NCT01943617 | Jun 2013 → Dec 2016 | cirrhosis of liver | Beijing Friendship Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01938820 | Jun 2013 → Dec 2016 | cirrhosis of liver | Beijing Friendship Hospital | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07382375 | Dec 2027 expected | aortic disorder | Nanjing Medical University | Not yet recruiting | No outcome recorded |
| — | NCT06966687 | Apr 2025 → Dec 2026 expected | aortic aneurysm | Nanjing Medical University | Enrolling by invitation | No outcome recorded |
| — | NCT06607926 | Oct 2024 → Jun 2025 overdue | non-small cell lung carcinoma | Xuanwu Hospital, Beijing | Not yet recruiting | No outcome recorded |
| — | NCT06598839 | Jun 2024 → Sep 2025 overdue | non-small cell lung carcinoma | Yousheng Mao | Recruiting | No outcome recorded |
| — | NCT05339529 | Jul 2022 → Dec 2025 overdue | aortic disorder | Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT05487469 | Jul 2022 → Dec 2023 | rheumatic heart disease | Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT03082885 | Apr 2017 → Jun 2019 | liver failure | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT03509688 | Nov 2014 → Dec 2017 | hepatitis | The First Hospital of Jilin University | Completed | No outcome recorded |
| — | NCT00711620 | May 2008 → Dec 2010 | infectious disease with sepsis | Sun Yat-sen University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06552598 Background | Apr 2024 → Apr 2028 expected | cervical cancer, endometrial cancer | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00197860 Background | Sep 2004 → Dec 2009 | renal cell carcinoma | Inge Marie Svane | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02127268 Comparator | Apr 2014 → Apr 2020 | myalgic encephalomeyelitis/chronic fatigue syndrome | Zhigang Zhang | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00291616 Comparator | Dec 2005 → Aug 2008 | chronic hepatitis B virus infection | Seoul National University Hospital | Completed | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 69 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymalfasin | “Concurrent administration of thymalfasin and rhGM-CSF.” NCT06552598 ↗ |
| Known as | Ta1 | “Thymalfasin (Thymosin alpha 1, Ta1)” NCT02906150 ↗3“Thymalfasin (Thymosin alpha 1, Ta1)” NCT02906163 ↗ “Thymalfasin (Thymosin alpha 1, Ta1)” NCT06821100 ↗ “Thymalfasin (Thymosin alpha 1, Ta1)” NCT06829355 ↗ |
| Known as | Talpha1 | “Thymosin alpha1 (Talpha1), first described and characterized by Allan Goldstein in 1972, is used worldwide for the treatment of some immunodeficiencies, malignancies, and infections.” PMID 17495242 ↗ May 20072“Talpha1, a naturally occurring thymic peptide, primes dendritic cells (DCs) for antifungal T-helper type 1 resistance through Toll-like receptor 9 (TLR9) signaling.” PMID 16741252 ↗ Jun 2006 “In this study we examined the effect of the synthetic peptide thymosin-alpha1 (T(alpha)1) on MHC class I expression in FRTL-5 cells.” PMID 10741392 ↗ Mar 2000 |
| Known as | Thy-α1 | “Patients were treated with entecavir (ETV) or ETV + thymosin-alpha1 (Thy-α1) or lamivudine (LAM) + adefovir (ADV).” PMID 33460002 ↗ Jan 2021 |
| Known as | Thymalfasine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103979 ↗ |
| Known as | Thymosin a1 | “A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha...” NCT00911443 ↗ |
| Known as | Thymosin alpha 1 | “This is a randomized, double-blinded, multicenter trial to determine the effectiveness of thymosin alpha 1 (thymalfasin) 1.6 mg twice weekly plus PEGinterferon alfa-2a 180...” NCT00040027 ↗40“In this post hoc analysis, we aimed to evaluate whether metabolic abnormalities impact the effect of immune-enhancing thymosin alpha-1 (Tα1) therapy in acute necrotizing...” PMID 38356344 ↗ Feb 2024 “The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel/pemetrexed, cisplatin, Bevacizumab, iparomlimab and tuvonralimab, and thymosin alpha 1.” NCT07103395 ↗ “Thymosin alpha 1 (Tα1) is widely used to treat patients with COVID-19 in China; however, its efficacy remains unclear.” PMID 34408744 ↗ Aug 2021 “whether sequential combination therapy with Thymosin alpha 1 and entecavir is superior to continuous ETV monotherapy” NCT03448744 ↗ “Patients were treated with entecavir (ETV) or ETV + thymosin-alpha1 (Thy-α1) or lamivudine (LAM) + adefovir (ADV).” PMID 33460002 ↗ Jan 2021 “Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission.” NCT05487469 ↗ “Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission.” NCT05339529 ↗ “Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma” NCT00911443 ↗ “Immuno-chemotherapy regimen included etoposide, cisplatin, iparomlimab and tuvonralimab, and thymosin alpha 1.” NCT07103408 ↗ “Thymosin Alpha 1(1.6mg Biw)will be Subcutaneous injection from the fist week to the 12th weeks.” NCT02976740 ↗ “Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level.” PMID 10741392 ↗ Mar 2000 “1,6 mg Thymosin alpha 1 (Zadaxin®, SciClone) is administered s.c. twice a week” NCT00197860 ↗ “Thymalfasin (Thymosin alpha 1, Ta1)” NCT06829355 ↗ “Thymalfasin (Thymosin alpha 1, Ta1)” NCT02906163 ↗ “Thymalfasin (Thymosin alpha 1, Ta1)” NCT02906150 ↗ “Thymalfasin (Thymosin alpha 1, Ta1)” NCT06821100 ↗ “Thymalfasin (thymosin alpha-1)” NCT00082082 ↗ “thymalfasin (thymosin alpha 1)” NCT00039962 ↗ “Drug: thymosin alpha 1” NCT03659578 ↗ |
| Known as | Thymosin α1 | “This Phase II study is to determine the efficacy of Thymosin α1 on the frequency of acute pneumonia in non-small cell lung cancer with bulky tumor.” NCT03659578 ↗7“The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC” NCT06139419 ↗ “Thymosin α1 (Tα1) immunomodulatory activity on effector cells of the innate immunity has been extensively described” PMID 23050812 ↗ Oct 2012 “Thymosin-α1 (Tα1) is a naturally occurring thymic peptide with immune-modulatory properties.” NCT07675980 ↗ |
| Known as | Thymosin-α | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01943617 ↗ |
| Known as | Thymosins thymalfasin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103979 ↗ |
| Known as | Timalfasina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103979 ↗ |
| Known as | Tα1 | “In this post hoc analysis, we aimed to evaluate whether metabolic abnormalities impact the effect of immune-enhancing thymosin alpha-1 (Tα1) therapy in acute necrotizing...” PMID 38356344 ↗ Feb 20248“Thymosin α1 (Tα1), a thymosin-related 28-mer synthetic amino-terminal acetylated peptide, has gained increasing interest in recent years, due to its pleiotropy.” PMID 23045964 ↗ Oct 2012 “Since it was first identified, thymosin alpha 1 (Tα1) has been characterized to have pleiotropic effects on several pathological conditions” PMID 23045967 ↗ Oct 2012 “Thymosin alpha-1 (Tα-1) has shown clinical benefits in patients whose immune functions are severely compromised or ineffective.” NCT06178146 ↗ “Thymosin alpha 1 (Tα1) is widely used to treat patients with COVID-19 in China; however, its efficacy remains unclear.” PMID 34408744 ↗ Aug 2021 “Thymosin-α1 (Tα1) is a naturally occurring thymic peptide with immune-modulatory properties.” NCT07675980 ↗ “thymosin alpha 1 (Tα1) is considered as a promising beneficial immunomodulatory drug.” PMID 23327199 ↗ Jan 2013 “Thymosin-α1 (T-α1), a synthetic 28-amino acid peptide” NCT02127268 ↗ “thymosin alpha 1 (Tα1) supplementation” PMID 40367062 ↗ May 2025 |
| Known as | Zadaxin | “1,6 mg Thymosin alpha 1 (Zadaxin®, SciClone) is administered s.c. twice a week” NCT00197860 ↗3“ZADAXIN® (trade name; thymalfasin generic; Ta1 for short)” NCT06821100 ↗ |
| Action | Activate | “beneficial clinical effects of Ta1 result from activation of toll-like receptor (TLR) 9” NCT04428008 ↗ |
| Modality | Peptide | “a synthetic 28-amino acid peptide” NCT02127268 ↗ |
| Route | Subcutaneous | “1,6 mg Thymosin alpha 1 (Zadaxin®, SciClone) is administered s.c. twice a week” NCT00197860 ↗ |
| Target | TLR9 | “through Toll-like receptor 9 (TLR9) signaling” PMID 16741252 ↗ Jun 2006 |